Sitagliptin

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Sitagliptin (brand name Januvia) — Antidiabetic; DPP-4 inhibitor.

Identification

• Therapeutic class: Antidiabetic.
• Pharmacologic class: DPP-4 inhibitor.

Pharmacology

• Mechanism of action: Inhibits DPP-4, increasing incretin hormones to enhance glucose-dependent insulin release and lower glucagon.
• Onset / peak / duration: Peak 1 to 4 hours; once-daily effect.
• Half-life / therapeutic level: Half-life about 12 hours; no routine level.

Clinical use

• Indications: Type 2 diabetes.
• Usual dose, route, frequency: 100 mg PO once daily.
• Maximum dose / adjustments: Reduce dose in renal impairment (50 mg or 25 mg).

Safety

• Contraindications: Type 1 diabetes, history of serious hypersensitivity.
• Black box warning: None.
• Interactions: Few; additive hypoglycemia with insulin or sulfonylureas.
• Pregnancy / lactation: Limited data; insulin preferred.
• High-alert: No.

Adverse effects

• Common side effects: Nasopharyngitis, headache, upper respiratory symptoms.
• Serious effects to report: Pancreatitis (severe abdominal pain), severe joint pain, hypersensitivity.
• Antidote / reversal: None.

Nursing process

• Assessment before administration: Renal function, pancreatitis history.
• Interventions during therapy: Adjust dose by renal function.
• Monitor: A1c, renal function.
• Evaluation / expected outcome: Glycemic control, weight neutral.

Patient teaching

• Patient teaching: Report severe abdominal or joint pain.
• Notify provider if: Severe stomach pain, persistent vomiting.
• Administration tips: With or without food.